– No approvability issues identified by FDA related to efficacy or
CMC –
BOCA RATON, Fla.--(BUSINESS WIRE)--May 8, 2017--
TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare
company, today announced that it received a Complete Response Letter
(CRL) from the U.S. Food and Drug Administration (FDA) regarding the New
Drug Application (NDA) for TX-004HR, the company’s investigational
applicator-free estradiol vaginal softgel capsule for the treatment of
moderate-to-severe vaginal pain during sexual intercourse (dyspareunia),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
In the CRL, the only approvability concern raised by the FDA was the
lack of long-term endometrial safety data for TX-004HR beyond the
12-weeks studied in the pivotal phase 3 Rejoice Trial. No cases of
endometrial hyperplasia were observed in the Rejoice Trial at the end of
week 12 for all the doses studied and included in the NDA.
The CRL did not identify any issues related to the efficacy of TX-004HR
and did not identify any approvability issues related to chemistry,
manufacturing, and controls.
The Company believes that the NDA was approvable as filed and intends to
meet with the FDA as soon as possible to address the concerns raised by
the FDA.
“While we are disappointed that the NDA for TX-004HR was not approved at
this time and respectfully disagree with the FDA’s decision, we believe
there are multiple paths forward to address the concerns raised by the
FDA. The FDA has encouraged us to request a meeting to discuss our path
forward and we intend to meet with the FDA as quickly as possible,” said
TherapeuticsMD CEO Robert G. Finizio. “We are also continuing to prepare
the NDA for TX-001HR, our investigational oral bio-identical combination
of estradiol and progesterone, and anticipate that we will submit that
NDA to the FDA as early as the third quarter of 2017.”
Conference Call Today
As previously announced, TherapeuticsMD will host a conference call
today to discuss the TX-004HR regulatory update. Details for the call
are:
|
|
|
|
|
|
|
Date:
|
|
|
|
|
|
Monday, May 8, 2017
|
Time:
|
|
|
|
|
|
8:00 a.m. ET
|
Telephone Access (US):
|
|
|
|
|
|
866-665-9531
|
Telephone Access (International):
|
|
|
|
|
|
724-987-6977
|
Access Code for All Callers:
|
|
|
|
|
|
6935590
|
|
|
|
|
|
|
|
Additionally, a live webcast can be accessed on the company’s website, www.therapeuticsmd.com,
on the Home Page or under the “Investors & Media” section. A digital
recording of the conference call will be available for replay beginning
two hours after the call's completion and for at least 30 days with the
dial-in 855-859-2056 or international 404-537-3406 and Conference ID:
6935590.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s late stage clinical pipeline includes two phase 3 product
candidates: TX-001HR for treatment of moderate-to-severe vasomotor
symptoms (VMS) due to menopause and TX-004HR for treatment of
moderate-to-severe vaginal pain during sexual intercourse (dyspareunia),
a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The
company also manufactures and distributes branded and generic
prescription prenatal vitamins under the vitaMedMD® and
BocaGreenMD® brands.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that the company
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. Important factors that could cause actual results,
developments and business decisions to differ materially from
forward-looking statements are described in the sections titled “Risk
Factors” in the company’s filings with the Securities and Exchange
Commission, including its most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and
include the following: the company’s ability to resolve the deficiencies
identified by the FDA in the company’s new drug application for its
TX-004HR product candidate and the time frame associated with such
resolution; whether the company will be able to prepare an amended NDA
for its TX-004HR product candidate and, if prepared, whether the FDA
will accept and approve the NDA; the company’s ability to maintain or
increase sales of its products; the company’s ability to develop and
commercialize its hormone therapy drug candidates and obtain additional
financing necessary therefor; whether the company will be able to
prepare an NDA for its TX-001HR product candidate and, if prepared,
whether the FDA will accept and approve the NDA; the length, cost and
uncertain results of the company’s clinical trials; the potential of
adverse side effects or other safety risks that could preclude the
approval of the company’s hormone therapy drug candidates; the company’s
reliance on third parties to conduct its clinical trials, research and
development and manufacturing; the availability of reimbursement from
government authorities and health insurance companies for the company’s
products; the impact of product liability lawsuits; the influence of
extensive and costly government regulation; the volatility of the
trading price of the company’s common stock and the concentration of
power in its stock ownership. PDF copies of the company’s historical
press releases and financial tables can be viewed and downloaded at its
website: www.therapeuticsmd.com/pressreleases.aspx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170508005454/en/
Source: TherapeuticsMD, Inc.
TherapeuticsMD, Inc.
David DeLucia, 561-961-1900
Director,
Investor Relations
David.DeLucia@TherapeuticsMD.com